![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
富尔泽拉西布:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|November 25, 2024
概括
富尔泽拉西布是一种新的口服药物,向晚期非小细胞肺癌 (NSCLC) 中的KRAS G12C突变. 它最近在中国获得批准,用于以前接受过全身治疗的患者.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 富尔泽拉西布是一种口服活性小分子抑制剂,向KRAS G12C突变蛋白.
- 这种突变是各种固体瘤的关键驱动因素,包括非小细胞肺癌 (NSCLC) 和结直肠癌.
研究的目的:
- 总结一下Fulzerasib的发展里程碑.
- 为了记录该药物的首次批准用于治疗KRAS G12C突变高级NSCLC.
主要方法:
- 对富尔泽拉西布 (fulzerasib) 的临床开发数据的审查.
- 对II期研究结果的分析支持该药物的疗效.
主要成果:
- 富尔泽拉西布于2024年8月21日在中国获得了第一个有条件批准.
- 批准是针对KRAS G12C突变高级NSCLC的成年人,至少经过一线全身治疗后.
结论:
- 富尔泽拉西布代表了针对KRAS G12C突变NSCLC的向治疗的重大进展.
- 该药物的开发突出了针对瘤疾病的精密医学的进展.
更多相关视频
08:36Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
995
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.3K
相关概念视频
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
78
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
78
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K